MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 24, 2006; DOI: 10.1124/mol.106.028126


0026-895X/06/7005-1602-1611$20.00
Mol Pharmacol 70:1602-1611, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.028126v1
70/5/1602    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urban, T. J.
Right arrow Articles by Giacomini, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urban, T. J.
Right arrow Articles by Giacomini, K. M.

Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5)

Thomas J. Urban, Renata C. Gallagher, Chaline Brown, Richard A. Castro, Leah L. Lagpacan, Claire M. Brett, Travis R. Taylor, Elaine J. Carlson, Thomas E. Ferrin, Esteban G. Burchard, Seymour Packman, and Kathleen M. Giacomini

Departments of Biopharmaceutical Sciences (T.J.U., C.B., R.A.C., L.L.L., E.G.B., K.M.G.), Pediatrics (R.C.G., S.P.), Anesthesiology (C.M.B.), Genome Core Facility (T.R.T., E.J.C.), and Pharmaceutical Chemistry (T.E.F.), University of California San Francisco, San Francisco, California

Systemic carnitine deficiency (SCD) is a rare autosomal recessive disease resulting from defects in the OCTN2 (SLC22A5) gene, which encodes the high-affinity plasma membrane carnitine transporter. Although OCTN2 is fairly well studied in its relationship with SCD, little is known about the carrier frequency of disease-causing alleles of OCTN2, or of more common functional polymorphisms in this gene. To address these issues, we screened for genetic variants in the OCTN2 coding region by direct sequencing of the exons and flanking intronic region of OCTN2 in a large sample (n = 276) of ethnically diverse subjects. In addition, we established lymphoblastoid cell lines from subjects homozygous for either allele of the previously identified promoter region variant, -207G>C. We found eight amino acid sequence variants of OCTN2, of which three (Phe17Leu, Leu144Phe, and Pro549Ser) were polymorphic in at least one ethnic group. When assayed for functional activity by expression in human embryonic kidney 293 cells, using as probes both the endogenous substrate (L-carnitine) and the organic cation tetraethylammonium, three variants showed functional differences from the reference OCTN2 (Phe17Leu, Tyr449Asp, Val481Phe; p < 0.05). Further studies of the Phe17Leu polymorphism showed a reduced Vmax for L-carnitine transport to approximately 50% of the reference OCTN2. Confocal microscopy studies using an OCTN2-GFP fusion protein showed that Phe17Leu had distinct subcellular localization from the reference OCTN2, with diffuse cytoplasmic retention of Phe17Leu, in contrast to reference OCTN2, which localized specifically to the plasma membrane. Lymphoblasts from subjects homozygous for the -207G allele showed increased L-carnitine transport compared with the -207C/C homozygotes (p < 0.05). This study suggests that although loss-of-function mutations in OCTN2 are likely to be rare, common variants of OCTN2 found in healthy populations may contribute to variation in the disposition of carnitine and some clinically used drugs.


Received June 19, 2006; accepted August 24, 2006

Address correspondence to: Dr. Kathleen M. Giacomini, Department of Biopharmaceutical Sciences, 1550 4th Street, RH584, Box 2911, University of California, San Francisco, CA 94143-2911. E-mail: kmg{at}itsa.ucsf.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. Abla, L. W. Chinn, T. Nakamura, L. Liu, C. C. Huang, S. J. Johns, M. Kawamoto, D. Stryke, T. R. Taylor, T. E. Ferrin, et al.
The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 859 - 868.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. D. Cropp, T. Komori, J. E. Shima, T. J. Urban, S. W. Yee, S. S. More, and K. M. Giacomini
Organic Anion Transporter 2 (SLC22A7) Is a Facilitative Transporter of cGMP
Mol. Pharmacol., April 1, 2008; 73(4): 1151 - 1158.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Huang, V. Agrawal, K. M. Giacomini, and W. L. Miller
Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations
PNAS, February 5, 2008; 105(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics